Outwitting the blood-brain barrier for therapeutic purposes: Osmotic opening and other means

Neurosurgery

Volumn 42, Issue 5, 1998, Pages 1083-1100

  Kroll, Robert A ^a   Neuwelt, Edward A ^a,b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b PORTLAND VA MEDICAL CENTER   (United States)

Author keywords

Animal studies; Blood Brain barrier; Blood Brain barrier disruption; Brain tumor; Clinical studies; Treatment

Indexed keywords

ANESTHETIC AGENT; ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT; BRADYKININ; CARBOPLATIN; CHLORMETHINE; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOFOS; ETOPOSIDE; FOLINIC ACID; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN G ANTIBODY; IODINE 131; IRON OXIDE; ISOFLURANE; MANNITOL; METHOTREXATE; MITOMYCIN C; MONOCLONAL ANTIBODY; PENTOBARBITAL; PRODRUG; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RUBIDIUM 82; SODIUM THIOSULFATE; TRITIUM; UNINDEXED DRUG; VINCA ALKALOID; VINCRISTINE;

ANIMAL MODEL; BLOOD BRAIN BARRIER; BRAIN LYMPHOMA; BRAIN TUMOR; CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG INDUCED DISEASE; DRUG TARGETING; GENE THERAPY; GLIOMA; HEARING LOSS; HUMAN; INTRAARTERIAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LYSOSOME STORAGE DISEASE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NAUSEA; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME;

EID: 0031965788     PISSN: 0148396X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006123-199805000-00082     Document Type: Review

References (79)

1. Abbott NJ, Romero IA: Transporting therapeutics across the blood-brain barrier. Mol Med Today 2:106-113, 1996.
2. Barth RF, Yang W, Rotaru JH, Moeschberger ML, Joel DD, Nawrocky MM, Goodman JH, Soloway AH: Boron neutron capture therapy of brain tumors: Enhanced survival following intracarotid injection of either sodium borocaptate or boronophenylalanine with or without blood-brain barrier disruption. Cancer Res 57:1129-1136, 1997.
3. Berk BC, Corson MA, Peterson TE, Tseng H: Protein kinases as mediators of fluid shear stress stimulated signal transduction in endothelial cells: A hypothesis for calcium-dependent and calcium-independent events activated by flow. J Biomech 28: 1439-1450, 1995.
4. Blasberg RG, Groothuis D, Molnar P: A review of hyperosmotic blood-brain barrier disruption in seven experimental brain tumor models, in Johansson BB, Owman C, Widner H (eds): Pathophysiology of the Blood-Brain Barrier. Amsterdam, Elsevier, 1990, pp 197-220.
5. Bobo RH, Laske DW, Akbasak A, Morrison PF, Dedrick RL, Oldfield EH: Convection-enhanced delivery of macromolecules in the brain. Proc Natl Acad Sci U S A 91:2076-2080, 1994.
6. Brem H, Ewend MG, Piantadosi S, Greenhoot J, Burger PC, Sisti M: The safety of interstitial chemotherapy with BCNU-loaded polymer followed by radiation in the treatment of newly diagnosed malignant gliomas: Phase I trial. J Neurooncol 26:111-123, 1995.
7. Brem H, Piantadosi S, Burger PC, Walker M, Selker R, Vick NA, Black K, Sisti M, Brem S, Mohr G, Muller P, Morawetz R, Schold SC: Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. Lancet 345:1008-1012, 1995.
8. Brightman MW: The distribution within the brain of ferritin injected into cerebrospinal fluid compartments. J Cell Biol 26: 99-123, 1965.
9. Brightman MW, Hori M, Rapoport SI, Reese TS, Westergaard E: Osmotic opening of tight junctions in cerebral endothelium. J Comp Neurol 152:317-325, 1973.
10. Brodie BB, Kurz H, Schanker LS: The importance of dissociation constant and lipid-solubility in influencing the passage of drugs into the cerebrospinal fluid. J Pharmacol Exp Ther 130: 20-25, 1960.
11. Broman T, Olsson O: Experimental study of contrast media for cerebral angiography with reference to possible injurious effects on the cerebral blood vessels. Acta Radiol 31:321-334, 1949.
12. Capala J, Barth RF, Bendayan M, Lauzon M, Adams DM, Soloway AH, Fenstermaker RA, Carlsson J: Boronated epidermal growth factor as a potential targeting agent for boron neutron capture therapy for brain tumors. Bioconjug Chem 7:7-15, 1996.
13. Crossen JR, Garwood A, Glatstein E, Neuwelt EA: Neurobehavioral sequelae of cranial irradiation in adults: A review of radiation induced encephalopathy. J Clin Oncol 12:627-642, 1994.
14. Dahlborg SA, Henner WD, Crossen JR, Tableman M, Petrillo A, Braziel R, Neuwelt EA: Non-AIDS primary CNS lymphoma: The first example of durable response in a primary brain tumor using enhanced chemotherapy delivery without cognitive loss and without radiotherapy. Cancer J Sci Am 2:166-174, 1996.
15. 14a. Dahlborg SA, Petrillo A, Crossen JR, Roman-Goldstein S, Doolittle ND, Fuller KH, Neuwelt EA: The potential for complete and durable response in non-glial primary brain rumors in pediatric patients and young adults with enhanced chemotherapy delivery. Cancer J Sci Am (in press).
16. Dascalu A, Oron Y, Nevo Z, Korenstein R: Hyperosmotic modulation of the cytosolic calcium concentration in a rat osteoplastlike cell line. J Physiol (Lond) 486:97-104, 1995.
17. Davson H: The environment of the neurone. Trends Neurosci 1:39-41, 1978.
18. Doran SE, Ren XD, Betz AL, Pagel MA, Neuwelt EA, Roessler BJ, Davidson BL: Gene expression from recombinant viral vectors in the CNS following blood-brain barrier disruption. Neurosurgery 36:965-970, 1995.
19. Ehrlich P: Uber die Beziehungen von chemische Constituion, Vertheilung, und Pharmakologischer Wirkung: Collected Studies in Immunity. New York, John Wiley, 1906, pp 567-595.
20. Finlay JL, Goldman S, Wong MC, Cairo M, Garvin J, August C, Cohen BH, Stanley P, Zimmerman RA, Bostrom B, Geyer JR, Harris RE, Sanders J, Yates AJ, Boyett JM, Packer RJ: Pilot study of high-dose thiotepa and etoposide with autologous bone marrow rescue in children and young adults with recurrent CNS rumors. J Clin Oncol 14:2495-2503, 1996.
21. Gancher ST, Crabbe J, Garland A, Lea E, Woodward W: Dose and duration-dependent tolerance to rotational effects of apomorphine in a rat model of parkinsonism. J Pharmacol Exp Ther 272:275-281, 1995.
22. Goldmann EE: Die äussere und innere sekretion des genden und gekranken Organismus im Licht der vitalen Färbung. Beitr Klin Chir 64:192-265, 1909.
23. Goldmann EE: Vitalfärbung am Zentralnervensystem. Abh Preuss Akad Wiss Phys-Math 1:1-60, 1913.
24. Hall WA, Flores EP, Low WC: Antisense oligonucleotides for central nervous system tumors. Neurosurgery 38:376-383, 1996.
25. Heideman RL, Kovnar EH, Kellie SJ, Douglass EC, Gajjar AJ, Walter AW, Langston JA, Jenkins JJ, Li Y, Greenwald C: Preirradiation chemotherapy with carboplatin and etoposide in newly diagnosed embryonal pediatric CNS tumors. J Clin Oncol 13:2247-2254, 1995.
26. Huwyler J, Wu D, Pardridge WM: Brain drug delivery of small molecules using immunoliposomes. Proc Natl Acad Sci USA 93:14164-14169, 1996.
27. Inamura T, Black KL: Bradykinin selectively opens blood-tumor barrier in experimental brain rumors. J Cereb Blood Flow Metab 14:862-870, 1994.
28. Inamura T, Nomura T, Bartus RT, Black KL: Intracarotid infusion of RMP-7, a bradykinin analog: A method for selective drug delivery to brain tumors. J Neurosurg 81:752-758, 1994.
29. Karnovsky MJ: The ultrastructural basis of capillary permeability studied with peroxidase as a tracer. J Cell Biol 35:213-236, 1967.
30. Kerr DE, Schreiber GJ, Vrudhula VM, Svensson HP, Hellström I, Hellström KE, Senter PD: Regressions and cures of melanoma xenografts following treatment with monoclonal antibody β-lactamase conjugates in combination with anticancer prodrugs. Cancer Res 55:3558-3563, 1995.
31. Kroll RA, Pagel MA, Langone JJ, Neuwelt EA: Differential permeability of the blood-tumor barrier in intracerebral tumor-bearing rats: Anti-drug antibody to achieve systemic drug rescue. Therap Immunol 1:333-341, 1994.
32. Kroll RA, Pagel MA, Muldoon LL, Neuwelt EA: Increasing volume of distribution to brain with interstitial infusion: Dose, rather than convection, may be the most important factors. Neurosurgery 38:746-754, 1996.
33. Laske DW, Ilercil O, Akbasak A, Youle RJ, Oldfield EH: Efficacy of direct intratumoral therapy with targeted protein toxins for solid human gliomas in nude mice. J Neurosurg 80:520-526, 1994.
34. Lieberman DM, Laske DW, Morrison PF, Bankiewicz KS, Oldfield EH: Convection-enhanced distribution of large molecules in gray matter during interstitial drug infusion. J Neurosurg 82: 1021-1029, 1995.
35. Markowsky SJ, Zimmerman CL, Tholl D, Soria I, Castillo R: Methotrexate disposition following disruption of the blood-brain barrier. Ther Drug Monit 13:24-31, 1991.
36. Matsukado K, Inamura T, Nakano S, Fukui M, Bartus RT, Black KL: Enhanced tumor uptake of carboplatin and survival in glioma-bearing rats by intracarotid infusion of bradykinin analog, RMP-7. Neurosurgery 39:125-133, 1996.
37. Miller DC, Hochberg FH, Harris NL, Gruber ML, Louis DN, Cohen H: Pathology with clinical correlations of primary nervous system non-Hodgkin's lymphoma: The Massachusetts General Hospital experience 1958-1989. Cancer 74:1383-1397, 1994.
38. Modjtahedi H, Dean C: The receptor for EGF and its ligands: Expression, prognostic value and target for therapy in cancer. Int J Oncol 4:227-296, 1991.
39. Muldoon LL, Nilaver G, Kroll RA, Pagel MA, Breakefield XO, Chiocca EA, Davidson BL, Weissleder R, Neuwelt EA: Comparison of intracerebral inoculation and osmotic blood-brain barrier disruption for delivery of adenovirus, herpesvirus and iron oxide particles to normal rat brain. Am J Pathol 147:1840-1851, 1995.
40. 38a. Muldoon LL, Pagel MA, Kroll RA, Roman-Goldstein S, Neuwelt EA: Demonstration of a physiologic barrier distal to the anatomic blood-brain barrier. Proceedings of the American Association for Cancer Research. Presented at the 89th Annual Meeting, New Orleans, Louisiana, March 28-April 1, 1998.
41. M2 gangliosidosis (Sandhoff disease). Am J Pathol 144:1109-1118, 1994.
42. Nakano S, Matsukado K, Black KL: Increased brain tumor microvessel permeability after intracarotid bradykinin infusion is mediated by nitric oxide. Cancer Res 56:4027-4031, 1996.
43. Nazzaro JM, Rosenbaum LC, Pagel MA, Neuwelt EA: A new model of systemic drug rescue based on permeability characteristics of the blood-brain barrier in intracerebral abscess-bearing rats. J Neurosurg 74:467-474, 1991.
44. Neuwelt EA (ed): Implications of the Blood-Brain Barrier and Its Manipulation. New York, Plenum Press, 1989, vol 1 and 2.
45. Neuwelt EA, Kroll RA: Osmotic blood-brain barrier modification: Increasing delivery of diagnostic and therapeutic agents to the brain, in Flanagan TR, Emerich DF, Winn SR (eds): Providing Pharmacological Access to the Brain: Methods in Neuroscience. San Diego, Academic Press, 1994, vol 21, pp 52-67.
46. Neuwelt EA, Barnett PA, Hellström I, Hellström KE, Beaumier P, McCormick CI, Weigel RM: Delivery of melanoma-associated immunoglobulin monoclonal antibody and Fab fragments to normal brain utilizing osmotic blood-brain barrier disruption. Cancer Res 48:4723-4729, 1988.
47. Neuwelt EA, Brummett RE, Remsen LG, Kroll RA, Pagel MA, McCormick CI, Guitjens S, Muldoon LL: In vitro and animal studies of sodium thiosulfate as a potential chemoprotectant against carboplatin-induced ototoxicity. Cancer Res 56:706-709, 1996.
48. Neuwelt EA, Frenkel EP, Rapoport S, Barnett P: Effect of osmotic blood-brain barrier disruption on methotrexate pharmacokinetics in the dog. Neurosurgery 7:36-43, 1980.
49. M2 gangliosidosis (Sandhoff's disease) in Korat cats. J Clin Invest 76:482-190, 1985.
50. Neuwelt EA, Pagel MA, Geller AI, Muldoon LL: Gene replacement therapy in the central nervous system: Viral vector-mediated therapy of global neurodegenerative disease. Behav Brain Sci 18:1-9, 1995.
51. Neuwelt EA, Specht HD, Barnett PA, Dahlborg SA, Miley A, Larson SM, Brown P, Eckerman KF, Hellström KE, Hellström I: Increased delivery of tumor-specific monoclonal antibodies to brain after osmotic blood-brain barrier modification in patients with melanoma metastatic to the central nervous system. Neurosurgery 20:885-895, 1987.
52. Neuwelt EA, Weissleder R, Nilaver G, Kroll RA, Roman-Goldstein S, Szumowski J, Pagel MA, Jones RS, Remsen LG, McCormick CI, Shannon EM, Muldoon LL: Delivery of virus-sized iron oxide particles to rodent CNS neurons. Neurosurgery 34:777-784, 1994.
53. Neuwelt EA, Williams PC, Mickey BE, Frenkel EP, Henner WD: Therapeutic dilemma of disseminated CNS germinoma and the potential of increased platinum-based chemotherapy delivery with osmotic blood-brain barrier disruption. Pediatr Neurosurg 21:16-22, 1994.
54. Nilaver G, Muldoon LL, Kroll RA, Pagel MA, Breakefield XO, Davidson BL, Neuwelt EA: Delivery of herpesvirus and adenovirus to nude rat intracerebral tumors following osmotic blood-brain barrier disruption. Proc Natl Acad Sci U S A 92:9829-9833, 1995.
55. Nomura T, Inamura T, Black KL: Intracarotid infusion of bradykinin selectively increases blood-tumor permeability in 9L and C6 brain tumors. Brain Res 659:62-66, 1994.
56. Oldfield EH, Ram Z, Culver KW, Blaese RM, DeVroom HL, Anderson WF: Gene therapy for the treatment of brain tumors using intra-tumoral transduction with the thymidine kinase gene and intravenous ganciclovir. Hum Gene Ther 4:39-69, 1993.
57. Prokai-Tatrai K, Prokai L, Bodor N: Brain-targeted delivery of a leucine-enkephalin analogue by retrometabolic design. J Med Chem 39:4775-4782, 1996.
58. Ram Z, Culver KW, Oshiro EM, Viola JJ, DeVroom HL, Otto E, Long Z, Chiang Y, McGarrity GJ, Muul LM, Katz D, Blaese RM, Oldfield EH: Summary of results and conclusions of the gene therapy of malignant brain tumors clinical study. Proceedings of the AANS, Denver, April 22-27, 1995.
59. Rapoport SI: Effect of concentrated solutions on blood-brain barrier. Am J Physiol 219:270-274, 1970.
60. Rapoport SI: Blood-Brain Barrier in Physiology and Medicine. New York, Raven Press, 1976.
61. Rapoport SI, Robinson PJ: Tight-junctional modification as the basis of osmotic opening of the blood-brain barrier. Ann N Y Acad Sci 481:250-267, 1986.
62. Rapoport SI, Hori M, Klatxo I: Testing of a hypothesis of osmotic opening of the blood-brain barrier. Am J Physiol 223:323-331, 1972.
63. Reese TS, Karnovsky MJ: Fine structural localization of a blood-brain barrier to exogenous peroxidase. J Cell Biol 34:208-217, 1967.
64. Remsen LG, McCormick CI, Roman-Goldstein S, Nilaver G, Weissleder R, Bogdanov A, Hellström KE, Hellström I, Kroll RA, Neuwelt EA: MR of carcinoma-specific monoclonal antibody conjugated to monocrystalline iron oxide nanopartides: The potential for noninvasive diagnosis. AJNR Am J Neuroradiol 17:411-418, 1996.
65. Remsen LG, McCormick CI, Sexton G, Pearse HD, Garcia R, Mass M, Roman-Goldstein S, Neuwelt EA: Long-term toxicity and neuropathology associated with the sequencing of cranial irradiation and enhanced chemotherapy delivery. Neurosurgery 40:1034-1042, 1997.
66. Remsen LG, McCormick CI, Sexton G, Pearse HD, Garcia R, Neuwelt EA: Decreased delivery and acute toxicity of cranial irradiation and chemotherapy given with osmotic blood-brain barrier disruption in a rodent model: The issue of sequence. Clin Cancer Res 1:731-739, 1995.
67. Robinson PJ, Rapoport SI: Model For drug uptake by brain tumors: Effects of osmotic treatment and of diffusion in brain. J Cereb Blood Flow Metab 11:165-168, 1991.
68. Roman-Goldstein SM, Barnett PA, McCormick CI, Ball MJ, Ramsey F, Neuwelt EA: Effects of gadopentetate dimeglumine administration after osmotic blood-brain barrier disruption: Toxicity and MR imaging findings. AJNR Am J Neuroradiol 12:885-890, 1991.
69. Roman-Goldstein SM, Barnett PA, McCormick CI, Szumowski J, Shannon EM, Ramsey FL, Mass M, Neuwelt EA: Effects of Gd-DTPA after osmotic BBB disruption in a rodent model: Toxicity and MR findings. J Comput Assist Tomogr 18:731-736, 1994.
70. Roman-Goldstein S, Clunie DA, Stevens J, Hogan R, Monard J, Ramsey F, Neuwelt EA: Osmotic blood-brain barrier disruption: CT and radionuclide imaging. AJNR Am J Neuroradiol 15:581-590, 1994.
71. Stern L, Gautier R: Rapports entre le liquide céphalo-rachidien et la circulation sanquine. Arch Int Physiol 17:138-192, 1921.
72. Stern L, Gautier R: Les rapports entre le liquide céphalo-rachidien et les éléments nerveux de l'axe cérébrospinal. Arch Int Physiol 17:391-448, 1922.
73. Trail PA, Willner D, Lasch SJ, Henderson AJ, Hofstead S, Casazza AM, Firestone RA, Hellström I, Hellström KE: Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates. Science 261:212-215, 1993.
74. Walter KA, Tamargo RJ, Olivi A, Burger PC, Brem H: Intratumoral chemotherapy. Neurosurgery 37:1129-1145, 1995.
75. Wang Q, Patton WF, Chiang ET, Hechtman HB, Shepro D: Filamen translocation is an early endothelial cell inflammatory response to bradykinin: Regulation by calcium, protein kinases, and protein phosphatases. J Cell Biochem 62:383-396, 1996.
76. Williams PC, Henner WD, Roman-Goldstein S, Dahlborg SA, Brummett RE, Tableman M, Dana BW, Neuwelt EA: Toxicity and efficacy of carboplatin and etoposide in conjunction with disruption of the blood-brain barrier in the treatment of intracranial neoplasms. Neurosurgery 37:17-28, 1995.
77. Yang W, Barth RF, Carpenter DE, Moeschberger ML, Goodman JH: Enhanced delivery of boronophenylalanine by means of intracarotid injection and blood-brain barrier disruption for neutron capture therapy. Neurosurgery 38:985-992, 1996.
78. Zünkeler B, Carson RE, Olson J, Blasberg RG, DeVroom H, Lutz RJ, Saris SC, Wright DC, Kammerer W, Patronas NJ, Dedrick RL, Herscovitch P, Oldfield EH: Quantification and pharmacokinetics of blood-brain barrier disruption in humans. J Neurosurg 85:1056-1065, 1996.
79. Zünkeler B, Carson RE, Olson J, Blasberg RG, Girton M, Bacher J, Herscovitch P, Oldfield EH: Hyperosmolar blood-brain barrier disruption in baboons: An in vivo study using positron emission tomography and rubidium-82. J Neurosurg 84:494-502, 1996.